The issue of the C-shares which subsequently were converted into ordinary shares has entailed an increase in the number of ordinary shares and votes of 832,213. The exercise of TO 2 has entailed an increase in the number of ordinary shares and votes in the Company of 17,776,856. The total number of ordinary shares in the Company thus amounts to 47,016,521 and the total number of votes amounts to 47,016,521 as of June 28[th], 2024, the last trading day of the month.

At the date of this press release, the Company holds 1,186,522 own ordinary shares.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail:mark.beveridge@mobergpharma.se

About this information
This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:00 CEST on June 28[th], 2024, through the contact persons above.

About Moberg Pharma, www.mobergpharma.com (http://www.mobergpharma.se)
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015, is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden under the brand name Terclara[®] and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).